OLD Category: immuno-oncology

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

• Balko J. et al.,

GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1β/IL1R1 response

• De Marco P. et al.,

PILOT AND FEASIBILITY TRIAL OF IMMUNO-GENE THERAPY OF MALIGNANT MESOTHELIOMA USING INTRAPLEURAL DELIVERY OF ADENOVIRUS- INTERFERON-ALPHA COMBINED WITH CHEMOTHERAPY

• Sterman D.H. et al.,

Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc

• D'Artista L. et al.,

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype

• Gabrusiewicz K et al.,

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

• Peng W. et al.,

Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer

• Kroeger D.R. et al.,

The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis

• Vogelsang M. et al.,

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

• Legrier M-E. et al.,

Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways

• Sefert L. et al.,

Comprehensive functional characterization of cancer–testis antigens defines obligate participation in multiple hallmarks of cancer

• Maxfield K.E. et al.,

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triplenegative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

• Loi S. et al.,